期刊
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
卷 48-49, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2020.101691
关键词
Chemotherapy; Molecular targeted therapy; Gastrointestinal; Toxicity
资金
- Wellcome Trust (UK)
- Health Research Board (Ireland) [203930/B/16/Z]
- Health Service Executive National Doctors Training and Planning (Ireland)
- Health and Social Care, Research and Development Division (Northern Ireland)
Treatment-related acute gastrointestinal toxicities are a common and often debilitating hurdle encountered in the treatment of cancer patients. While the introduction of targeted therapies such as tyrosine kinase inhibitors has led to improvements in survival outcomes, their use has also been complicated by a high frequency of clinically important adverse effects. Gastrointestinal toxicities such as nausea, vomiting, diarrhoea and hepatotoxicity represent potentially serious adverse events that may necessitate dose reductions, treatment interruptions and cessation of treatment. An improved knowledge of the incidence, pathophysiology, management and prophylaxis of these toxicities is crucial in order to reduce patient morbidity and mortality. In this review, we discuss the main gastrointestinal toxicities associated with chemotherapy and targeted therapies in oncology, outlining their incidence, pathophysiology and expert management guidelines. (C) 2020 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据